Skip to content Credex Healthcare provides molecular lab billing services for independent molecular diagnostics laboratories, hospital-based molecular pathology departments, reference labs, and genomics companies. We deal with prior authorization denials for genetic panels, ICD-10 medical-necessity mismatches, and the compliance exposure that comes with billing molecular diagnostic codes without the requisition documentation to support them.
Credex Healthcare’s molecular lab revenue cycle management handles the full billing cycle, from requisition review and prior authorization through claim submission, denial management, and payment reconciliation for every test your laboratory reports.
First-pass claim approval rate
Average molecular lab billing turnaround
Medicare, Medicaid & commercial networks
Prior authorization & requisition documentation review
Credex Healthcare has a separate payment method for genetic labs that looks over each request before entering a charge. Our billing experts at the molecular lab make sure that the CPT code chosen matches the exact gene and method described in the test report, that the ICD-10 diagnosis code on the requisition meets the payer’s medical necessity criteria for that genetic test under the relevant LCD or NCD, and that permission was obtained before the specimen was processed for any test that needs payer approval. Molecular lab billing mistakes and fixes cost a lot because tests are pricey, strict prior authorization rules apply, and a single paperwork error on a multigene panel claim can lead to a rejection worth thousands of dollars.
Our molecular lab billing services in the USA cover the following:
Claims are submitted with confirmed CPT codes that match the gene being analyzed, correct ICD-10 diagnosis pairs, and prior authorization on file for every type of test that needs insurer approval. Our team follows up on decisions in real time and makes sure they are made before deadlines.
We handle enrollment for molecular labs with Medicare, Medicaid, and private insurance companies. This includes verifying their CLIA high-complexity certification and adding molecular pathology as a specialty, so your lab can send out bills from a legal enrollment state.
Molecular claims that are denied are looked at again within 48 hours. The claim was turned down because of an LCD absence, a medical-necessity mismatch, a prior authorization gap, or a CPT code precision error. Our team fixes it and resends it with the supporting clinical data and insurance policy.
Our trained coders check test reports and requests against molecular diagnostic billing codes 81235, 81270, 81479, 87635, and the full range of 81200-81479 gene-specific codes. They do this to make sure that the chosen CPT code is supported by the analytical method, gene being analyzed, and clinical indication.
Most commercial insurers must approve genetic cancer panels, pharmacogenomic testing, somatic mutation panels, and certain molecular tests for infectious diseases ahead of time. Before specimens are handled, we start, track, and record authorizations. This way, no high-cost panel is recorded and then turned down.
End-to-end RCM includes reviewing requisitions, capturing charges in a way that is compliant with CLIA rules, keeping track of previous authorizations, processing payments, reconciling contracted rates, and sending monthly reports so that lab managers have accurate collection data by test type and customer every billing cycle.
Credex Healthcare is a molecular lab billing company in the USA that oversees changes in Medicare Local Coverage Determinations for molecular pathology testing across MAC regions. They also monitor changes in commercial payer prior-authorization requirements for hereditary cancer panels and pharmacogenomic testing, and keep up with the latest molecular diagnostic billing standards across the full CPT 81200-81479 code set. If a genetic test has a relevant LCD or NCD, the clinical reason meets the approved diagnostic standards, and the test was ordered by a doctor with a documented clinical context, Medicare will pay for it. There are various complex rules governing who can pay for and cover next-generation sequencing kits and multigene genetic tests.
Medicare covers molecular pathology tests under Part B when medical necessity is established, and the test falls within covered indications under the applicable LCD or NCD. We manage Medicare molecular billing across all MAC jurisdictions, applying correct gene-specific CPT codes, medical-necessity documentation standards, and CLFS rates for each test.
Medicaid coverage for molecular and genetic testing varies significantly by state. Some programs cover hereditary cancer panels for specific populations. Others limit coverage to specific diagnostic indications. Our team maintains state-specific Medicaid molecular billing rules and applies them correctly to every claim.
Hereditary cancer panels, including BRCA1/2, Lynch syndrome testing, and expanded hereditary cancer panels, require payer-specific prior authorization, gene-specific CPT code selection, and clinical indication documentation that links the test to the patient's personal or family history. We manage hereditary panel billing as a dedicated workflow.
Pharmacogenomics testing and somatic tumor mutation panels carry their own billing rules, LCD requirements, and prior authorization pathways. Somatic panels for oncology use specific CPT codes and require pathology-confirmed tissue documentation. We manage pharmacogenomics and somatic panel billing separately from germline testing workflows.
Molecular lab claims are turned down for clear reasons, such as CPT codes that were chosen for the wrong specificity level for the gene being analyzed, ICD-10 codes that don't meet the payer's LCD criteria for that test, not getting prior authorizations before processing expensive panels, and requests that don't include the clinical indication language that proves medical necessity. Before a claim is sent out, Credex Healthcare looks over all of that.
Every molecular lab claim is verified against your active CLIA high-complexity certificate, billing NPI, and payer-specific lab enrollment status before submission. A lapsed CLIA certification or an incorrect CLIA number on a molecular claim is one of the fastest routes to an immediate rejection and a compliance flag.
We audit test reports against gene-specific CPT codes, including 81235 (EGFR gene analysis), 81270 (JAK2 gene analysis), 81479 (unlisted molecular pathology), and 87635 (SARS-CoV-2 RNA detection), confirming that the code selected matches the specific gene, mutation type, and analytical methodology documented in the laboratory report.
Each molecular test must be linked to a diagnosis code that meets the payer's LCD or NCD criteria for that specific gene and clinical indication. We review every diagnosis-to-test pairing before charge entry and flag requisitions where the clinical indication does not support coverage under the applicable LCD.
Prior authorization for genetic testing is tracked by test category and payer. Authorization is obtained before high-cost hereditary panels, pharmacogenomics tests, and somatic mutation panels are processed. Approval documentation is attached to claims at submission, and renewal timelines are monitored for patients on recurring molecular testing protocols.
Medicare MACs apply different LCDs to the same molecular test, whereas commercial payers apply their own coverage policies and step-therapy requirements for genetic testing. We maintain current molecular coverage guides for every payer in your test volume and apply the correct rules to each claim.
Accounts Receivable Follow-Up
Molecular lab AR is reviewed weekly. High-dollar denied claims are escalated immediately before the timely filing limits close. Underpayments are checked against the Medicare CLFS rate or contracted fee schedule, and LCD exclusion disputes are appealed with the clinical documentation and ordering physician context that the MAC requires.
Molecular labs lose income because of billing mistakes that are harder to find than normal lab rejections. EGFR panels were billed under 81479 as unnamed because the biller didn’t know that 81235 was the correct code. This caused payment delays and required each claim to be reviewed by hand. Because the ordering doctor’s office handled the authorization request and didn’t check for approval before the tissue was collected, BRCA genetic panels were run, and reports were sent out without first obtaining permission. CMS denied pharmacogenomics panels because the ICD-10 number on the request didn’t match the approved conditions in that MAC’s LCD. Before any claim is made, Credex Healthcare’s molecular lab billing process checks all three.
End-to-end molecular lab insurance billing from requisition review and gene-specific CPT code selection through prior authorization verification and electronic claim submission to Medicare, Medicaid, and commercial payers for every test in the billing queue.
Our molecular lab billing specialists apply the correct molecular diagnostic and genetic testing billing codes for each test method and gene, cutting the denials due to CPT code specificity errors and ICD-10 medical necessity mismatches.
Prior Authorization Management
Prior authorization for genetic testing is tracked from requisition intake through approval confirmation. No hereditary cancer panel, pharmacogenomics test, or somatic mutation panel is processed without confirming the authorization status against the ordering payer's requirements.
Denial management for molecular lab claims covers LCD exclusion disputes, CPT code specificity corrections, medical-necessity documentation appeals, and prior authorization gap resolutions. Each appeal is built around the specific test report, clinical indication, and payer LCD that supports coverage.
Provider application management covers CLIA high-complexity certification verification, molecular lab NPI enrollment, billing physician credentialing, and ongoing recredentialing, so your laboratory bills without interruption as payer agreements renew.
Monthly reports cover collections by test category and payer, molecular diagnostic denial trends by CPT code, prior authorization compliance rate, molecular lab claim reimbursement timeline by carrier, and AR aging so lab administrators have the data to manage revenue performance.
Years of Molecular Lab Billing Expertise
Lab Enrollment & Credentialing Success
Claim Compliance Rate Across All Payer
Support Available for All Your Needs
Customized Molecular Lab Revenue Cycle Solutions
MD
Ngozi
“Many of our molecular panel claims were being billed under 81479 as unnamed treatments because our billing team couldn’t keep up with the gene-specific code changes in the 81200 range. Each 81479 claim is looked over by hand, which takes between 60 and 90 days. Credex linked each test on our menu to a specific CPT code and changed the charge master. As a result, our average time to get reimbursed dropped from over 70 days to less than 30 days. The revenue impact of getting off unlisted codes was substantial.”
Lab Director
Sandra
“Hereditary cancer panel prior authorization was our biggest billing problem. Ordering physicians were submitting requisitions and expecting us to handle the PA, but we had no system for tracking which payers required it or whether approval had been received before we ran the panel. We were reporting results and then getting denied post-collection. Credex built a PA tracking system tied to the requisition intake workflow. Panels do not go to analysis until the authorization status is confirmed for that payer. The write-offs on unauthorized panels dropped to near zero.”
MD
Kwame
“Somatic tumor mutation panel billing is complicated because CPT code selection depends on the number of genes analyzed and the methodology, and those details must come from the pathology report and the test methodology document, not the requisition. Our billers were using a single code for all NGS panels regardless of panel size. Credex matched the coding to the actual panel composition from the lab report, corrected the charge master by panel type, and our somatic panel billing accuracy went from around 65% correct to over 90% in the first quarter.”
Revenue Director
Adaeze
“We run molecular testing for ordering physicians across 12 states. The LCD differences across MAC jurisdictions meant that the same hereditary panel was covered in some states and denied in others based on the specific diagnosis code on the requisition. Credex built a payer-by-MAC coverage matrix for our test menu and applies the correct ICD-10 pairing for each ordering state. Medicare molecular denials dropped from 19% to 6% in the first three months.”
MD
Fatou
“Pharmacogenomics billing is genuinely confusing because the coverage policies change frequently, and the clinical validity standards differ by payer and by gene. Our previous billing approach was to submit and appeal whatever was denied, which was inefficient and left a lot of money in AR limbo. Credex tracks the pharmacogenomics LCD updates by MAC, flags tests before submission when the diagnosis does not meet coverage criteria, and our pharmacogenomics denial rate went from 28% down to 8% within two billing cycles.”
Lab Billing Assessment
We audit your current molecular billing workflow, CPT code accuracy review against your test menu, CLIA certification and NPI status, prior authorization tracking gaps, ICD-10 medical necessity compliance by payer and MAC, AR aging by test category, and denial history by reason code.
Credentialing & Payer Enrollment
We check your molecular lab NPI, CLIA high-complexity approval, and payment enrollment status. Before new claims are sent in, any gaps in service application management are addressed. For professional component claims that apply, billing physicians' credentials are checked.
CPT Code Mapping & Authorization Setup
We link each test on your lab's menu to the right gene-specific CPT code and update the charge master accordingly. We also identify any tests that must be approved by a payer first, and create a requisition-tracking system to ensure the PA status is confirmed before specimens are processed.
Clean Claim Submission
Our molecular lab billing experts review every request and test report, ensure the CPT code matches the gene and method, verify the ICD-10 matches the relevant LCD, include proof of prior authorization, and send claims electronically to Medicare, Medicaid, and private payers.
Denial Management & Follow-Up
As a claim moves through the process, it is tracked. Within 48 hours, denials are looked over again. There is a specific way to handle LCD exclusion appeals, CPT code precision corrections, and previous authorization gap fixes. Each one is based on the test report, the clinical reason, and the payer's coverage policy.
Reporting & Ongoing Optimization
Monthly reports cover collections by test category and payer, molecular diagnostic denial trends by CPT code, prior authorization compliance rate, molecular lab billing turnaround time, and AR aging. CPT code mapping and LCD compliance updates are applied as payer policies change.
Molecular lab billing involves not just standard codes. The CPT code set is gene-specific and methodology-specific. The LCD requirements vary by MAC region for the same test. The prior authorization requirements for hereditary panels and pharmacogenomics testing differ by payer and change frequently. The compliance risk from billing unlisted codes when specific codes exist is real. Credex Healthcare focuses on molecular lab medical billing because this discipline requires billing specialists who understand the molecular pathology code set and stay current with policy changes affecting it.
Our team works on molecular and genetic lab claims. We know how gene-specific CPT codes in the 81200 to 81479 range are selected, how LCD requirements differ by MAC region for the same hereditary panel, how pharmacogenomics coverage policies are structured, and where molecular lab billing errors most commonly create both revenue loss and compliance exposure.
Your laboratory works with one dedicated molecular lab billing specialist who knows your test menu, payer contracts, CLIA scope, and the recurring denial patterns in your claims. Billing issues are handled by someone who already understands the test methodology and the billing context.
Lab administrators see collections by test category and payer, molecular diagnostic denial trends, prior authorization compliance rate, CPT code accuracy by test type, molecular lab billing turnaround time, and AR aging in monthly reports that reflect the laboratory’s actual financial position.
Genetic test results, patient requisitions, and molecular pathology reports handled throughout the billing process are protected under full HIPAA compliance protocols, including the heightened privacy requirements that apply to genetic information under GINA and state genetic privacy laws.
Molecular labs lose revenue through billing errors that compound test by test. Panels were billed under unlisted codes because the charge master was never mapped to the gene-specific CPT codes. Hereditary panels were processed without prior authorization because the requisition intake workflow did not include an authorization check. Medicare denials on pharmacogenomics tests because the ICD-10 code did not match the MAC’s LCD criteria. An audit identifies all of those in the first few weeks and quantifies the revenue impact for each test category.
Credex Healthcare starts with a free review of your current molecular lab billing: CPT code accuracy review against your test menu, prior authorization tracking gaps, ICD-10 medical necessity compliance by MAC and payer, CLIA enrollment status, and AR aging by test category. No commitment required to get that review. We identify the recoverable revenue and the specific charge master and workflow changes that prevent those losses from continuing.
Gene-specific CPT numbers from 81200 to 81479 are used for billing at molecular labs. The CPT 81235 code covers an EGFR gene study to determine whether lung cancer patients are eligible for targeted treatment. The course CPT 81270 covers analysis of the JAK2 gene for myeloproliferative neoplasms. The unnamed molecular pathology code 81479 is used when there isn’t a unique code for the test that was done. Nucleic acid amplification is used to find SARS-CoV-2 RNA (CPT 87635).
In some cases, yes. Part B of Medicare pays for molecular pathology tests when a Local Coverage Determination or a National Coverage Determination says they are medically necessary. Coverage depends on the gene being tested, the reason for the test, and whether the test has an ICD-10 code covered under the LCD in the patient’s MAC area. Commercial funders have their own rules about what they will cover. These rules include needing prior authorization, requiring step treatment for genetic testing groups, and clinical usefulness factors that differ by gene and indication.
It takes 14 to 30 days for Medicare to process clean electronic molecular lab claims when the CPT code matches the test report paperwork, and the ICD-10 diagnosis meets the LCD standards. Commercial payers usually pay within 30 days, provided there is proof of prior authorization and clinical indication. Claims sent with the code 81479 usually take 60 to 90 days to process because they must be reviewed by hand. When Medicaid applications are due varies by state, but they are usually 30 to 60 days.
The billing industry is rapidly evolving. By the year 2025, the system and tools used
Billing companies ensure compliance with HIPAA and other regulations by being legitimate and reliable. Every
At Credex Healthcare, we know how frustrating it is when claims are denied. That is
Fill the form and someone from our team will get back to you. Or you can also call us on (833) 477-1261.
